123 related articles for article (PubMed ID: 38617934)
1.
Zniber M; Lamminen T; Taimen P; Boström PJ; Huynh TP
Heliyon; 2024 Apr; 10(7):e28949. PubMed ID: 38617934
[TBL] [Abstract][Full Text] [Related]
2. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
4. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
5. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
7. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
11. Identification of characteristic metabolic panels for different stages of prostate cancer by
Zhang X; Xia B; Zheng H; Ning J; Zhu Y; Shao X; Liu B; Dong B; Gao H
J Transl Med; 2022 Jun; 20(1):275. PubMed ID: 35715864
[TBL] [Abstract][Full Text] [Related]
12. Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Logozzi M; Angelini DF; Giuliani A; Mizzoni D; Di Raimo R; Maggi M; Gentilucci A; Marzio V; Salciccia S; Borsellino G; Battistini L; Sciarra A; Fais S
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569672
[TBL] [Abstract][Full Text] [Related]
13. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
14. Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.
Jia G; Dong Z; Sun C; Wen F; Wang H; Guo H; Gao X; Xu C; Xu C; Yang C; Sun Y
Oncotarget; 2017 Sep; 8(44):76987-76999. PubMed ID: 29100363
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.
Amante E; Cerrato A; Alladio E; Capriotti AL; Cavaliere C; Marini F; Montone CM; Piovesana S; Laganà A; Vincenti M
Sci Rep; 2022 Mar; 12(1):4361. PubMed ID: 35288652
[TBL] [Abstract][Full Text] [Related]
16. Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men.
Mahaveer Chand N; Tekumalla PK; Rosenberg MT; Dobi A; Ali A; Miller GM; Aristizabal-Henao JJ; Granger E; Freedland SJ; Kellogg MD; Srivastava S; McLeod DG; Narain NR; Kiebish MA
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398103
[TBL] [Abstract][Full Text] [Related]
17. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
18. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience.
Moslemi MK; Lotfi F; Tahvildar SA
Cancer Manag Res; 2011; 3():227-31. PubMed ID: 21792331
[TBL] [Abstract][Full Text] [Related]
20. A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer.
Drago D; Andolfo A; Mosca E; Orro A; Nocera L; Cucchiara V; Bellone M; Montorsi F; Briganti A
Cancer Biol Med; 2021 May; 18(2):604-15. PubMed ID: 34037347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
